Transforming Growth Factor Beta 1 (TGFB1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
The transforming growth factor beta 1 (TGFB1) targeted pipeline therapeutics report provides comprehensive information on TGFB1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in transforming growth factor beta 1 targeted therapeutics development with respective active and dormant or discontinued projects.
What are the key route of administration in the transforming growth factor beta 1 targeted pipeline market?
The key route of administration in the transforming growth factor beta 1 targeted pipeline market are intravenous, inhalational, oral, intratumor, topical, intradermal, intraarterial, intraprostatic, intravenous drip, intravitreal, ophthalmic, and intraarticular.
Transforming growth factor beta 1 targeted pipeline market, by route of administration
For more route of administration insights, download a free sample
What are the key molecule type in the transforming growth factor beta 1 targeted pipeline market?
The key molecule type in the transforming growth factor beta 1 targeted pipeline market are monoclonal antibody, antisense RNAI oligonucleotide, small molecule, peptide, antisense oligonucleotide, fusion protein, gene therapy, synthetic peptide, antibody, and recombinant protein.
Transforming growth factor beta 1 targeted pipeline market, by key molecule type
For more molecule type insights, download a free sample
What are the key companies in the transforming growth factor beta 1 targeted pipeline market?
The key companies in the transforming growth factor beta 1 targeted pipeline market are AiViva BioPharma Inc, AskGene Pharma Inc, Avellino Lab USA Inc, Bonac Corp, Bristol-Myers Squibb Co, Certa Therapeutics Pty Ltd, Chengdu Huitai Biomedicine Co Ltd, Chugai Pharmaceutical Co Ltd, Ensol Biosciences Inc, Genoscience Pharma, Genzyme Corp, Guangzhou Nanxin Pharmaceutical Co Ltd, Hainan Haiyao Co Ltd, HitGen Inc, Isarna Therapeutics GmbH, Johnson & Johnson, Lepu Biopharma Co Ltd, Nanjing Shenghe Pharmaceutical Co Ltd, Novartis AG, Phio Pharmaceuticals Corp, Scholar Rock Inc, Sirnaomics Inc, and Sisaf Ltd.
Transforming growth factor beta 1 targeted pipeline market, by key companies
To know more about key companies, download a free sample
Market report overview
Key route of administration | Intravenous, Inhalational, Oral, Intratumor, Topical, Intradermal, Intraarterial, Intraprostatic, Intravenous Drip, Intravitreal, Ophthalmic, and Intraarticular |
Key molecule type | Monoclonal Antibody, Antisense Rnai Oligonucleotide, Small Molecule, Peptide, Antisense Oligonucleotide, Fusion Protein, Gene Therapy, Synthetic Peptide, Antibody, and Recombinant Protein |
Key companies | AiViva BioPharma Inc, AskGene Pharma Inc, Avellino Lab USA Inc, Bonac Corp, Bristol-Myers Squibb Co, Certa Therapeutics Pty Ltd, Chengdu Huitai Biomedicine Co Ltd, Chugai Pharmaceutical Co Ltd, Ensol Biosciences Inc, Genoscience Pharma, Genzyme Corp, Guangzhou Nanxin Pharmaceutical Co Ltd, Hainan Haiyao Co Ltd, HitGen Inc, Isarna Therapeutics GmbH, Johnson & Johnson, Lepu Biopharma Co Ltd, Nanjing Shenghe Pharmaceutical Co Ltd, Novartis AG, Phio Pharmaceuticals Corp, Scholar Rock Inc, Sirnaomics Inc, and Sisaf Ltd |
Scope
- The report provides a snapshot of the global therapeutic landscape for Transforming Growth Factor Beta 1 (TGFB1)
- The report reviews Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics.
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Transforming Growth Factor Beta 1 (TGFB1) Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Transforming Growth Factor Beta 1 (TGFB1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
AskGene Pharma Inc
Avellino Lab USA Inc
Bonac Corp
Bristol-Myers Squibb Co
Certa Therapeutics Pty Ltd
Chengdu Huitai Biomedicine Co Ltd
Chugai Pharmaceutical Co Ltd
Ensol Biosciences Inc
Genoscience Pharma
Genzyme Corp
Guangzhou Nanxin Pharmaceutical Co Ltd
HitGen Inc
Isarna Therapeutics GmbH
Johnson & Johnson
Lepu Biopharma Co Ltd
Nanjing Shenghe Pharmaceutical Co Ltd
Novartis AG
Phio Pharmaceuticals Corp
Scholar Rock Inc
Sirnaomics Inc
Sisaf Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key route of administration in the TGFB1 targeted pipeline market?
Intravenous, inhalational, oral, intratumor, topical, intradermal, intraarterial, intraprostatic, intravenous drip, intravitreal, ophthalmic, and intraarticular are the key route of administration in the TGFB1 targeted pipeline market.
-
What are the key molecule type in the TGFB1 targeted pipeline market?
Monoclonal antibody, antisense RNAI oligonucleotide, small molecule, peptide, antisense oligonucleotide, fusion protein, gene therapy, synthetic peptide, antibody, and recombinant protein are the key molecule type in the TGFB1 targeted pipeline market.
-
What are the key companies in the TGFB1 targeted pipeline market?
AiViva BioPharma Inc, AskGene Pharma Inc, Avellino Lab USA Inc, Bonac Corp, Bristol-Myers Squibb Co, Certa Therapeutics Pty Ltd, Chengdu Huitai Biomedicine Co Ltd, Chugai Pharmaceutical Co Ltd, Ensol Biosciences Inc, Genoscience Pharma, Genzyme Corp, Guangzhou Nanxin Pharmaceutical Co Ltd, Hainan Haiyao Co Ltd, HitGen Inc, Isarna Therapeutics GmbH, Johnson & Johnson, Lepu Biopharma Co Ltd, Nanjing Shenghe Pharmaceutical Co Ltd, Novartis AG, Phio Pharmaceuticals Corp, Scholar Rock Inc, Sirnaomics Inc, and Sisaf Ltd are the key companies in the TGFB1 targeted pipeline market.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.